^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    huCART19-IL18

    i
    Other names: huCART19-IL18
    Associations

    News

    Trials
    Company:
    University of Pennsylvania
    Drug class:
    CD19-targeted CAR-T immunotherapy, IL-18 stimulant
    Related drugs:
    Associations

    News

    Trials
    1year
    TmCD19-IL18 in CD19+ Cancers (clinicaltrials.gov)
    P1, N=24, Recruiting, University of Pennsylvania | Not yet recruiting --> Recruiting
    Enrollment open • CAR T-Cell Therapy
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD19 expression • BCL6 rearrangement • BCL2 rearrangement
    |
    huCART19-IL18
    over1year
    TmCD19-IL18 in CD19+ Cancers (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, University of Pennsylvania
    New P1 trial • CAR T-Cell Therapy
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6) • IGH (Immunoglobulin Heavy Locus) • IL18 (Interleukin 18)
    |
    CD19 expression • BCL6 rearrangement • BCL2 rearrangement
    |
    huCART19-IL18